- Altamira Therapeutics reported a **net loss** of **$1.5 million** for the first half of **2025**, a **64.6% decrease** from **$4.3 million** in the first half of **2024**, with the **operating loss** decreasing by **32.9%** to **$2.6 million**.  **[1601936_0001213900-25-082071_ea025475301ex99-3_altamira.htm:1]** **[1601936_0001213900-25-082071_ea025475301ex99-2_altamira.htm:3]**  However, cash and cash equivalents significantly decreased to **$4 thousand** as of **June 30, 2025**, from **$1.0 million** at year-end **2024**.  **[1601936_0001213900-25-082071_ea025475301ex99-3_altamira.htm:1]** **[1601936_0001213900-25-082071_ea025475301ex99-1_altamira.htm:1]** 
- The company is advancing plans for a **partial spin-off** of its RNA delivery business, operated through its Swiss subsidiary Altamira Therapeutics AG (ATAG), to involve private equity investors for funding.  **[1601936_0001213900-25-082071_ea025475301ex99-3_altamira.htm:0]** **[1601936_0001213900-25-082071_ea025475301ex99-2_altamira.htm:0]** **[1601936_0001213900-25-082071_ea025475301ex99-2_altamira.htm:1]** 
- The Board of Directors considers it feasible to generate **$2.8 million to $3.5 million** in funding within **12 months** from August 27, 2025, but notes that these plans have not yet been fully realized, raising substantial doubt about the company's ability to continue as a going concern.  **[1601936_0001213900-25-082071_ea025475301ex99-1_altamira.htm:5]** **[1601936_0001213900-25-082071_ea025475301ex99-2_altamira.htm:6]** 
- In 2025, Altamira secured **two new collaboration partners** for the evaluation of its xPhore RNA delivery platform, including for circular RNA (CycloPhore) and radiopharmaceutical applications.  **[1601936_0001213900-25-082071_ea025475301ex99-3_altamira.htm:0]** **[1601936_0001213900-25-082071_ea025475301ex99-2_altamira.htm:1]**

Altamira Therapeutics (CYTOF)